Walleye Capital LLC Acquires Shares of 347,898 Tyra Biosciences, Inc. $TYRA
Walleye Capital LLC has acquired a new stake of 347,898 shares in Tyra Biosciences, Inc. (NASDAQ:TYRA), valued at approximately $11.1 million, bringing institutional ownership in the company to 84.14%. Despite the stock opening at $25.29, well below its 52-week high, analysts maintain a "Moderate Buy" consensus rating with an average price target of $46.90. The company reported a quarterly loss of $0.69 per share, missing estimates.
TYRA Biosciences (TYRA) holder reports 3.55M-share, 6% beneficial stake
Nextech VI Oncology SCSp, along with related entities and individuals, has filed an amended Schedule 13G reporting a 6.0% beneficial ownership stake in TYRA Biosciences (TYRA). This amounts to 3,553,585 shares of common stock as of June 30, 2026. The filing indicates that Nextech VI GP S.a. r.l. and its managers Ian Charoub, Costas Constantinides, and Rocco Sgobbo collectively have the power to direct the voting and disposition of these shares, although they disclaim forming a "group" for reporting purposes.
Farallon group trims Tyra Biosciences (TYRA) holdings to 6,000 shares, 0% stake
Farallon Capital Management, L.L.C., along with several related investment entities and individuals, has filed an Amendment No. 2 to a Schedule 13G/A, reporting beneficial ownership of 6,000 shares of Tyra Biosciences (TYRA) common stock, which constitutes a 0% stake as of June 30, 2026. This filing indicates that the reporting group's ownership is now below the 5% threshold requiring more extensive disclosure. The shares are held across various Farallon Funds, with the investment manager and several managing members listed as reporting persons.
Avoiding Lag: Real-Time Signals in (TYRA) Movement
The article analyzes Tyra Biosciences Inc. (NASDAQ: TYRA), highlighting weak near-term and mid-term sentiment despite a long-term positive outlook. It provides AI-generated institutional trading strategies including position, momentum breakout, and risk hedging, along with multi-timeframe signal analysis and support/resistance levels.
CCORF Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Maintains Target Price $50
CCORF has reiterated its Buy rating for TYRA BIOSCIENCES, INC. (TYRA.US), along with maintaining its target price of $50. This suggests a continued positive outlook from the firm regarding the company's stock performance.
BofA Securities Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Cuts Target Price to $39
BofA Securities has reiterated its Buy rating for TYRA BIOSCIENCES, INC. (TYRA.US) but has revised its price target downward to $39. This adjustment reflects an updated outlook from the firm regarding the company's valuation.
Tyra Biosciences, Inc. Stock 12‑Month Price Target Cut to $50.82, Implies 94% Upside
Analysts have slightly cut the average 12-month price target for Tyra Biosciences, Inc. (TYRA) stock from $51.09 to $50.82, with individual forecasts ranging from $39 to $59. This updated target suggests a potential upside of approximately 94% based on the recent closing price. The consensus rating from 15 analysts remains a "Buy."
Wedbush Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Maintains Target Price $53
Wedbush has reiterated its Buy rating for TYRA Biosciences, Inc. (TYRA.US), maintaining a target price of $53. This indicates a continued positive outlook from the analyst firm regarding the company's stock performance.
Jefferies Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Raises Target Price to $42
Jefferies has reiterated its Buy rating on TYRA BIOSCIENCES, INC. (TYRA.US) and increased its price target to $42. This indicates a positive outlook from the firm regarding the company's future performance.
Tyra Biosciences, Inc. (NASDAQ:TYRA) Receives Consensus Rating of "Moderate Buy" from Brokerages
Tyra Biosciences, Inc. (NASDAQ:TYRA) has received a "Moderate Buy" consensus rating from fifteen research firms, with an average 12-month price target of $46.90. Despite this optimistic outlook, the company's shares recently declined by 21% to $25.71, trading below its 50-day and 200-day moving averages. Tyra Biosciences also reported a quarterly loss of $0.69 per share, missing analyst estimates.
Tyra Biosciences (TYRA) Reports Q2 Results, Is The Pipeline Potential Already Priced In?
Tyra Biosciences (TYRA) reported Q2 2026 results, showing a wider net loss but also experiencing significant share price momentum over the past year. The article questions whether the market has already fully priced in the potential of its development pipeline, given its 1-year total shareholder return of nearly 200%. While TYRA's price-to-book ratio of 5x is lower than some peers, it is still higher than the broader U.S. biotechs industry average, suggesting investors are betting heavily on future expectations despite current losses.
Tyra Biosciences (NASDAQ:TYRA) Shares Gap Down Following Weak Earnings
Tyra Biosciences (NASDAQ:TYRA) shares gapped down following a disappointing earnings announcement, missing the consensus EPS estimate. Despite this, analyst sentiment remains "Moderate Buy" with an average price target of $47.00. Institutional ownership is high at 84.14%, with several major investors increasing their stakes.
Tyra Biosciences posts Q2 2026 net loss $45.6M; cash $353.9M, runway into 2H 2028
Tyra Biosciences reported a Q2 2026 net loss of $45.6 million, ending the quarter with $353.9 million in cash, cash equivalents, and marketable securities, providing a runway into the second half of 2028. The company is advancing its dabogratinib programs, with key clinical readouts expected, including initial SURF302 data in September 2026 and BEACH301 sentinel results by the end of Q1 2027. R&D and G&A expenses totaled $39.2 million and $9.8 million, respectively, reflecting progress in their clinical trials.
Tyra Biosciences 2Q 2026: Net loss $45.6M, EPS $(0.69) — 10-Q Summary
Tyra Biosciences reported a net loss of $45.6 million, or $(0.69) per diluted share, for the second quarter of 2026, which is an increase from the $28.1 million net loss in the prior year. The company maintains a strong liquidity position with $353.9 million in cash, cash equivalents, and marketable securities. Tyra Biosciences is advancing its clinical programs, including dabogratinib in three Phase 2 trials and continued development of other pipeline candidates, while scaling up R&D activities and funding operations through at-the-market offerings.
Tyra Biosciences Reports Second Quarter 2026 Financial Results and Recent Highlights
Tyra Biosciences announced its second-quarter 2026 financial results, highlighted by initial Phase 2 data from SURF302 for bladder cancer expected in September 2026 and an expanded fifth dose level for the BEACH301 study in achondroplasia. The company reported $353.9 million in cash, cash equivalents, and marketable securities, providing a runway into the second half of 2028. Key strategic appointments and advancements in its dabogratinib 3x3 strategy for treating FGFR3-driven conditions were also detailed.
Janus Henderson Group PLC Acquires 955,147 Shares of Tyra Biosciences, Inc. $TYRA
Janus Henderson Group PLC has significantly increased its stake in Tyra Biosciences, Inc. (NASDAQ:TYRA) by purchasing an additional 955,147 shares, bringing its total holdings to 3.89 million shares valued at approximately $148.9 million. This acquisition makes Janus Henderson Group PLC one of the largest institutional holders with 6.54% of the company's stock, contributing to the overall institutional ownership of 84.14%. Despite a recent dip in share price and a quarterly earnings miss, analysts maintain a "Moderate Buy" rating for Tyra Biosciences with an average price target of $47.
Arkadios Wealth Advisors Makes New $1.82 Million Investment in Tyra Biosciences, Inc. $TYRA
Arkadios Wealth Advisors has made a new investment of $1.82 million in Tyra Biosciences, Inc., acquiring 47,567 shares. This comes as institutional investors and hedge funds collectively own a significant 84.14% of the company. Despite Tyra Biosciences missing its Q1 earnings estimates, analysts maintain a "Moderate Buy" rating with an average price target of $47.00.
Tyra Biosciences, Inc. $TYRA Stock Position Boosted by Seven Fleet Capital Management LP
Seven Fleet Capital Management LP significantly increased its stake in Tyra Biosciences (TYRA) by 149.6% in Q1 2026, holding 198,585 shares worth $7.6 million. This move is part of a broader trend of institutional investment, with several other firms also boosting their positions. Analysts maintain a "Moderate Buy" rating for TYRA with an average price target of $47.00, despite the company reporting a wider-than-expected Q1 loss.
Discipline and Rules-Based Execution in TYRA Response
This article analyzes Tyra Biosciences Inc. (NASDAQ: TYRA) using AI models to provide trading strategies. It highlights positive near-term sentiment within a long-term strength context, noting that support is being tested. The analysis identifies an exceptional risk-reward setup and offers distinct position, momentum breakout, and risk hedging trading strategies based on multi-timeframe signal analysis.
BlackRock (TYRA holder) reports 2.98M TYRA Biosciences shares, a 5% passive stake
BlackRock, Inc. has reported a 5% passive ownership stake in TYRA Biosciences, Inc., beneficially owning 2,976,228 shares of common stock. BlackRock holds sole voting power over 2,924,904 shares and sole dispositive power over all its beneficially owned shares. The filing indicates that no single underlying client of BlackRock holds more than five percent of TYRA’s total outstanding common shares.
Tyra Biosciences, Inc. $TYRA Shares Sold by Eversept Partners LP
Eversept Partners LP drastically reduced its stake in Tyra Biosciences (NASDAQ:TYRA) by 90.3% in the first quarter, selling over 251,000 shares. Despite this, institutional investors still collectively own a significant 84.14% of the company's stock, and Wall Street analysts maintain a "Moderate Buy" consensus rating with an average target price of $47. Tyra Biosciences, a clinical-stage oncology company, reported a quarterly loss that missed analyst estimates, but is actively developing small-molecule therapies for genetically defined cancers.
Tyra Biosciences Inc (TYRA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article from TradingKey attempts to provide a revenue breakdown for Tyra Biosciences Inc (TYRA), covering business segments, regional revenue, and profit contribution. However, the company has not yet disclosed the relevant financial data, leading to an empty report. The article essentially states that the requested information is unavailable.
Tyra Biosciences Inc (TYRA) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Tyra Biosciences Inc (TYRA) focusing on its dividend and stock split history. It states that the company has distributed $0.00 in dividends over the past five years, indicating no recent dividend payouts or stock splits. The financial snapshot shows TYRA's current stock price, market capitalization, and P/E TTM.
Tyra Biosciences Inc (TYRA) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Tyra Biosciences Inc (TYRA) stock, evaluating various indicators and moving averages. It summarizes the signals from MACD, RSI, KDJ, and others, indicating a neutral stance overall, with specific buy and sell signals from different metrics. The analysis aims to offer investors a reference for the stock's potential direction.
Tyra Biosciences Inc (TYRA) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis for Tyra Biosciences Inc (TYRA), focusing on its P/E and P/B ratios. However, it indicates that relevant data for these metrics have not yet been disclosed by the company. The page also presents current stock performance and market capitalization for TYRA.
Tyra Biosciences Inc (TYRA) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Tyra Biosciences Inc (TYRA), listing major shareholders like RA Capital Management, LP, Nextech Invest, Ltd., and Alta Partners with their respective proportions. It also breaks down shareholder types, institutional holdings over various reporting periods, and related ETF exposures. The data shows significant institutional and venture capital involvement in the company.
Tyra Biosciences Inc (TYRA) Cash Flow
This article provides a detailed historical cash flow statement for Tyra Biosciences Inc (TYRA), covering quarterly and annual data for operating, investing, and financing activities. It presents financial figures such as net income, operating cash flow, capital expenditures, and free cash flow, along with year-over-year percentage changes. The article also includes a FAQ section explaining key cash flow terms and their relevance to TYRA's financial health.
Tyra Biosciences Inc (TYRA) Earnings Forecast: Future EPS & Revenue Growth Estimates
The article provides an earnings forecast for Tyra Biosciences Inc (TYRA), noting a "Buy" rating from 16 analysts with a target price of $31.00. Analysts expect the company's EPS for the next quarter to be -$0.65, after a previous quarter's EPS of -$2.01 against an expectation of -$0.64. The company's stock currently trades at $30.63, with an upside space of 67.06%.
Tyra Biosciences Inc (TYRA) Risk Assessment: Volatility, Financial Risk & Investment Risk
This article provides a risk assessment for Tyra Biosciences Inc (TYRA), detailing various metrics related to volatility, financial risk, and investment risk. It includes data points such as Beta, Value at Risk (VaR), maximum drawdown, daily returns, Sharpe Ratio, and liquidity. The report offers a comprehensive overview of the stock's risk profile over different timeframes.
Tyra Biosciences Inc|Price:30.630|Chg%:-0.170
This article provides an overview of Tyra Biosciences Inc. (TYRA) stock, showing its current price, change, and market capitalization. It highlights that no stock score is available due to insufficient data but details how TradingKey generates its comprehensive stock scores, covering financial health, valuation, earnings forecast, price momentum, institutional confidence, and risk management.
Affinity Asset Advisors LLC Makes New $9.86 Million Investment in Tyra Biosciences, Inc. $TYRA
Affinity Asset Advisors LLC has made a new investment of $9.86 million in Tyra Biosciences, Inc., acquiring 257,512 shares, which represents about 0.43% of the company. Tyra Biosciences recently missed its Q1 earnings estimates, reporting EPS of -$0.64 against an expected -$0.60. Despite this, analysts maintain a "Moderate Buy" consensus rating with a target price of $47.00.
Tyra Biosciences (TYRA) Proxy filing Summary
Tyra Biosciences is holding its Annual Meeting on May 28, 2026, virtually. Shareholders will vote on the election of three Class II directors and the ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. The board recommends voting for all nominees and the auditor ratification.
Tyra Biosciences (TYRA) Q4 2025 earnings summary
Tyra Biosciences (TYRA) reported its Q4 2025 earnings, highlighting a strategic focus on three late-stage clinical studies for its dabogratinib program and an enhanced leadership team. Financially, the company ended 2025 with $256.0 million in cash, providing a runway through at least 2027, despite increased R&D and G&A expenses leading to a net loss of $33.8 million for the quarter. Key anticipated events include Phase 2 data readouts for SURF302 and BEACH301 in 2026, with the SURF303 study expected to begin patient dosing within the same year.
Tyra Biosciences (TYRA) Jefferies London Healthcare Conference 2025 Summary
Tyra Biosciences presented at the Jefferies London Healthcare Conference 2025, highlighting the progress of its lead drug, dabogratinib, an FGFR3 selective oral inhibitor. The drug is in Phase II trials for upper tract urothelial carcinoma, intermediate risk NMIBC, and achondroplasia, targeting multi-billion dollar markets with high unmet needs. Dabogratinib aims to offer a cleaner safety profile and potentially superior efficacy compared to existing pan-FGFR inhibitors and achondroplasia treatments, with key data readouts anticipated in the coming year.
Tyra Biosciences (TYRA) Bank of America Global Healthcare Conference 2026 Summary
Tyra Biosciences presented at the Bank of America Global Healthcare Conference 2026, highlighting the advancement of its highly selective FGFR3 inhibitor, dabogratinib, into late-stage development for three potential blockbuster indications: intermediate-risk NMIBC, UTUC, and achondroplasia. The company anticipates pivotal data readouts, including a 70% complete response rate target for NMIBC in August, initial UTUC data next year, and a six-month efficacy readout for achondroplasia in Q4 next year. Tyra Biosciences aims to disrupt large, underserved markets with oral therapies, offering significant advantages over current treatments.
Price to earnings forward of Tyra Biosciences, Inc. – NASDAQ:TYRA
This page from TradingView displays financial information for Tyra Biosciences, Inc. (NASDAQ:TYRA), specifically focusing on its price-to-earnings forward metric. The content indicates that market data is provided by ICE Data Services and FactSet, with SEC filings from Quartr.
Behavioral Patterns of TYRA and Institutional Flows
This article analyzes the behavioral patterns and institutional flows for Tyra Biosciences Inc. (NASDAQ: TYRA) using AI models. It identifies strong sentiment across all time horizons, supporting an overweight bias, and provides specific position trading, momentum breakout, and risk hedging strategies. The analysis highlights key support and resistance levels across near-term, mid-term, and long-term timeframes.
Price to sales forward of Tyra Biosciences, Inc. – BOATS:TYRA
The article discusses the "Price to sales forward" metric for Tyra Biosciences, Inc. (TYRA) on the TradingView platform. It provides financial data for the company, indicating the period, value, and change percentages for this metric. The page appears to be a financial data presentation devoid of narrative content.
Enterprise value to EBIT forward of Tyra Biosciences, Inc. – BOATS:TYRA
This article provides financial information for Tyra Biosciences, Inc. (TYRA) on the Blue Ocean Alternative Trade System (BOATS) via TradingView. It specifically highlights the company's enterprise value to EBIT forward data. The content appears to be a financial snapshot from a trading platform, indicating the market status as closed with no trades.
Wolfe Research initiates coverage of Tyra Biosciences (TYRA) with peer perform recommendation
Wolfe Research has initiated coverage of Tyra Biosciences (TYRA) with a "peer perform" recommendation. This suggests that Wolfe Research expects Tyra Biosciences to perform in line with its industry peers.
Enterprise value to EBITDA forward of Tyra Biosciences, Inc. – NASDAQ:TYRA
The article provides a title referencing the enterprise value to EBITDA forward for Tyra Biosciences, Inc. (NASDAQ: TYRA). It appears to be a stub or a section from a financial data platform like TradingView, offering navigation to financial data, news, and community features related to the company. The content itself does not contain any analytical data or detailed financial information regarding TYRA's enterprise value or EBITDA.
Tyra Biosciences, Inc.(NasdaqGS: TYRA) added to Russell 3000 Growth Benchmark
Tyra Biosciences, Inc. (NasdaqGS: TYRA) has been added to the Russell 3000 Growth Benchmark, a significant inclusion for the clinical-stage biotechnology company. This news follows several other index adjustments for the company on June 29 and 28, 2026, including additions to the Russell 2500 and 2000 Growth Benchmarks, and removals from various value and microcap indices. The company specializes in developing precision medicines using its SNAP platform, targeting FGFR biology for oncology and genetically defined conditions.
Is Tyra Biosciences, Inc. (TYRA) Stock a Biotech Opportunity Ahead of Key SURF302 Trial Data?
Tyra Biosciences, Inc. (TYRA) is positioned as a promising biotech stock due to upcoming clinical milestones, particularly the anticipated complete response data from its SURF302 study in August 2026. Oppenheimer initiated coverage with an "Outperform" rating and a $50 price target, citing the company's strong cash position and oral treatment approach. Despite reporting a net loss in Q1 2026 due to increased R&D expenses, analysts are optimistic about TYRA's potential in precision medicine for cancer.
Tyra Biosciences, Inc.(NasdaqGS: TYRA) added to Russell 2500 Growth Benchmark
Tyra Biosciences, Inc. (NasdaqGS: TYRA) has been added to the Russell 2500 Growth Benchmark, as well as the Russell 2000 Growth Benchmark and Russell 3000E Growth Benchmark. Concurrently, the company was dropped from several other Russell benchmarks, including the Russell Small Cap Comp Value Benchmark, Russell Microcap Index, Russell 3000 Value Benchmark, and Russell 2500 Value Benchmark. Tyra Biosciences is a clinical-stage biotechnology company focused on developing precision medicines targeting FGFR biology.
Tyra Biosciences, Inc.(NasdaqGS: TYRA) added to Russell 2000 Growth Benchmark
Tyra Biosciences, Inc. (NasdaqGS: TYRA) has been added to the Russell 2000 Growth Benchmark. This news comes alongside other recent index adjustments, including being dropped from several Russell Value and Microcap indices, but added to the Russell 3000E Growth Benchmark. The company is a clinical-stage biotechnology firm focused on developing precision medicines targeting FGFR biology.
(TYRA) Movement Within Algorithmic Entry Frameworks
The article provides an algorithmic analysis of Tyra Biosciences Inc. (NASDAQ: TYRA), indicating strong sentiment across all time horizons supporting an overweight bias. It outlines detailed institutional trading strategies, including position trading, momentum breakout, and risk hedging, with specific entry zones, targets, and stop losses. The analysis also highlights elevated downside risk due to a lack of additional long-term support signals.
Tyra Biosciences, Inc.(NasdaqGS: TYRA) dropped from Russell Microcap Index
Tyra Biosciences, Inc. (NasdaqGS: TYRA) has been removed from the Russell Microcap Index. This follows earlier reports of its exclusion from the Russell 3000 Value Benchmark and the Russell 2500 Value Benchmark. The company, a clinical-stage biotechnology firm, focuses on developing precision medicines targeting FGFR biology.
10 Most Promising Cancer Stocks According to Wall Street Analysts
This article identifies Tyra Biosciences, Inc. (NASDAQ:TYRA) as one of the most promising cancer stocks, citing an Outperform rating and $50 price target from Oppenheimer. The firm's confidence is based on upcoming clinical milestones, particularly full response data from the SURF302 study, and the company's strong cash position. Tyra Biosciences is a clinical-stage biotechnology company developing precision medicines for cancer.
Form 144 | TYRA BIOSCIENCES, INC.(TYRA.US) Insider Proposes to Sell 9.54 Million in Common Stocks
An insider at TYRA BIOSCIENCES, INC. (TYRA.US) has filed a Form 144 proposing to sell common stocks valued at $9.54 million. The filing indicates a significant potential transaction by an insider of the company.
Form 144 TYRA BIOSCIENCES For: 26 June By Investing.com
This article announces that TYRA Biosciences has filed a Form 144 for June 26. A Form 144 is a notice of the intent to sell restricted securities, indicating potential insider activity. The article provides only this brief detail and is published by Investing.com.
